DK1325033T3 - Inhibering af komplement C5 aktivering til behandlingen og forebyggelsen af forsinket xenograf- eller akut vaskulær afstødning - Google Patents
Inhibering af komplement C5 aktivering til behandlingen og forebyggelsen af forsinket xenograf- eller akut vaskulær afstødningInfo
- Publication number
- DK1325033T3 DK1325033T3 DK01977478.5T DK01977478T DK1325033T3 DK 1325033 T3 DK1325033 T3 DK 1325033T3 DK 01977478 T DK01977478 T DK 01977478T DK 1325033 T3 DK1325033 T3 DK 1325033T3
- Authority
- DK
- Denmark
- Prior art keywords
- inhibition
- treatment
- delayed
- acute vascular
- activation
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Transplantation (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US23930900P | 2000-10-10 | 2000-10-10 | |
PCT/US2001/031103 WO2002030985A2 (en) | 2000-10-10 | 2001-10-04 | Inhibition of complement c5 activation for the treatment and prevention of delayed xenograft or acute vascular rejection |
Publications (1)
Publication Number | Publication Date |
---|---|
DK1325033T3 true DK1325033T3 (da) | 2010-04-06 |
Family
ID=22901599
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK01977478.5T DK1325033T3 (da) | 2000-10-10 | 2001-10-04 | Inhibering af komplement C5 aktivering til behandlingen og forebyggelsen af forsinket xenograf- eller akut vaskulær afstødning |
Country Status (11)
Country | Link |
---|---|
US (1) | US6534058B2 (da) |
EP (5) | EP2281840A3 (da) |
AT (1) | ATE449791T1 (da) |
AU (1) | AU2001296594A1 (da) |
CA (1) | CA2424379C (da) |
DE (1) | DE60140618D1 (da) |
DK (1) | DK1325033T3 (da) |
ES (2) | ES2483991T3 (da) |
HK (3) | HK1134508A1 (da) |
PT (1) | PT1325033E (da) |
WO (1) | WO2002030985A2 (da) |
Families Citing this family (63)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ITMI20021527A1 (it) | 2002-07-11 | 2004-01-12 | Consiglio Nazionale Ricerche | Anticorpi anti componente c5 del complemento e loro uso |
CA2508302A1 (en) * | 2002-12-02 | 2004-06-17 | Resistentia Pharmaceuticals Ab | Methods and materials for treating inflammatory conditions using a polypeptide comprising a self-c5 amino acid segment and a non-self amino acid segment |
WO2004103288A2 (en) * | 2003-05-13 | 2004-12-02 | New York Society For The Ruptured And Crippled Maintaining The Hospital For Special Surgery | Method of preventing recurrent miscarriages |
EP1725659B1 (en) | 2004-03-01 | 2011-02-09 | Immune Disease Institute, Inc. | Natural igm antibodies and inhibitors thereof |
SI1755674T1 (sl) | 2004-05-14 | 2015-04-30 | Alexion Pharmaceuticals, Inc. | Podaljšanje preživetja alotransplantata z inhibiranjem aktivnosti komplementa |
US8168584B2 (en) | 2005-10-08 | 2012-05-01 | Potentia Pharmaceuticals, Inc. | Methods of treating age-related macular degeneration by compstatin and analogs thereof |
CN107929731A (zh) * | 2005-11-04 | 2018-04-20 | 健泰科生物技术公司 | 利用补体途径抑制剂治疗眼部疾病 |
AU2013200223B2 (en) * | 2005-11-04 | 2015-08-20 | Genentech, Inc. | Use of Complement Pathway Inhibitors to Treat Ocular Diseases |
SI1988882T1 (sl) | 2006-03-02 | 2015-07-31 | Alexion Pharmaceuticals, Inc. | Podaljšanje preživetja alografta z inhibiranjem aktivnosti komplementa |
US20090220508A1 (en) | 2006-03-15 | 2009-09-03 | Alexion Pharmaceuticals, Inc. | Treatment Of Paroxysmal Nocturnal Hemoglobinuria Patients By An Inhibitor Of Complement |
JP5624276B2 (ja) | 2006-03-31 | 2014-11-12 | 中外製薬株式会社 | 抗体の血中動態を制御する方法 |
EP2913342A1 (en) | 2006-09-05 | 2015-09-02 | Alexion Pharmaceuticals, Inc. | Compositions for use in the treatment of antibody mediated neuropathies |
ES2700609T3 (es) | 2006-11-02 | 2019-02-18 | Genentech Inc | Anticuerpos anti-factor D humanizados y sus usos |
HUE026001T2 (en) | 2007-02-05 | 2016-04-28 | Apellis Pharmaceuticals Inc | Compstatin analogues for use in the treatment of the inflammatory condition of the respiratory system |
EP3689912A1 (en) | 2007-09-26 | 2020-08-05 | Chugai Seiyaku Kabushiki Kaisha | Method of modifying isoelectric point of antibody via amino acid substitution in cdr |
TWI564021B (zh) | 2008-04-11 | 2017-01-01 | Chugai Pharmaceutical Co Ltd | Repeated binding of antigen to antigen binding molecules |
CR20170001A (es) | 2008-04-28 | 2017-08-10 | Genentech Inc | Anticuerpos anti factor d humanizados |
AU2014201433B2 (en) * | 2008-08-05 | 2016-05-26 | Novartis Ag | Compositions and methods for antibodies targeting complement protein C5 |
MX356218B (es) * | 2008-08-05 | 2018-05-18 | Novartis Ag | Composiciones y métodos para anticuerpos que se dirigen a la proteína de complemento c5. |
CN102448494B (zh) | 2009-02-13 | 2016-02-03 | 免疫医疗公司 | 具有胞内可裂解的键的免疫共轭物 |
CA2774260C (en) | 2009-09-16 | 2018-10-09 | Immunomedics, Inc. | Class i anti-cea antibodies and uses thereof |
CA2782194C (en) | 2009-12-02 | 2018-01-16 | Immunomedics, Inc. | Combination of radiolabelled antibodies (rait) and antibody-drug conjugates (adc) for treatment of pancreatic cancer |
MX365235B (es) | 2010-11-30 | 2019-05-28 | Chugai Pharmaceutical Co Ltd | Molécula de unión a antígeno capaz de unir repetidamente a la pluralidad de moléculas de antígeno. |
JP6024025B2 (ja) | 2011-05-02 | 2016-11-09 | イミューノメディクス、インコーポレイテッドImmunomedics, Inc. | 少容量投与用のアロタイプ選択抗体の限外濾過濃縮 |
JP6618682B2 (ja) | 2011-06-22 | 2019-12-11 | アペリス・ファーマシューティカルズ・インコーポレイテッドApellis Pharmaceuticals,Inc. | 補体阻害剤による慢性障害の治療方法 |
CN106831985A (zh) | 2011-12-21 | 2017-06-13 | 诺华股份有限公司 | 用于抗体靶定p因子的组合物和方法 |
KR102336895B1 (ko) | 2012-02-20 | 2021-12-08 | 스위디쉬 오르펀 바이오비트럼 에이비 (피유비엘) | 인간 보체 c5에 결합하는 폴리펩티드 |
CA2874864C (en) | 2012-08-14 | 2023-02-21 | Ibc Pharmaceuticals, Inc. | T-cell redirecting bispecific antibodies for treatment of disease |
TW201418707A (zh) * | 2012-09-21 | 2014-05-16 | Alexion Pharma Inc | 補體組分c5拮抗劑之篩選分析 |
SI3660033T1 (sl) | 2012-11-15 | 2021-09-30 | Apellis Pharmaceuticals, Inc. | Analogi kompstatina z dolgotrajnim delovanjem in sorodni sestavki in postopki |
WO2017004144A1 (en) | 2015-07-01 | 2017-01-05 | Immunomedics, Inc. | Antibody-sn-38 immunoconjugates with a cl2a linker |
PL2900277T3 (pl) | 2012-12-13 | 2022-05-16 | Immunomedics, Inc. | Dawkowanie immunokoniugatów przeciwciał i sn-38 dla poprawy skuteczności i zmniejszenia toksyczności |
CA2899589C (en) * | 2013-01-31 | 2022-02-22 | Seoul National University R & Db Foundation | C5 antibody and method for preventing and treating complement-related diseases |
WO2014152391A1 (en) | 2013-03-15 | 2014-09-25 | Apellis Pharmaceuticals, Inc. | Cell-penetrating compstatin analogs and uses thereof |
KR20180021234A (ko) | 2013-08-12 | 2018-02-28 | 제넨테크, 인크. | 보체-연관 상태의 치료를 위한 조성물 및 방법 |
DK3039033T3 (da) | 2013-08-28 | 2019-08-26 | Affibody Ab | Bindende polypeptider, der har et muteret skelet |
RU2733897C2 (ru) | 2013-08-28 | 2020-10-09 | Сведиш Орфан Биовитрум Аб (Пабл) | Стабильные полипептиды, связывающиеся с с5 комплемента человека |
WO2015126548A1 (en) | 2014-02-21 | 2015-08-27 | Ibc Pharmaceuticals, Inc. | Disease therapy by inducing immune response to trop-2 expressing cells |
WO2015130416A1 (en) | 2014-02-25 | 2015-09-03 | Immunomedics, Inc. | Humanized rfb4 anti-cd22 antibody |
WO2015168468A1 (en) | 2014-05-01 | 2015-11-05 | Genentech, Inc. | Anti-factor d antibody variants and uses thereof |
CA2953567C (en) | 2014-06-24 | 2023-09-05 | Immunomedics, Inc. | Anti-histone therapy for vascular necrosis in severe glomerulonephritis |
CN106999517A (zh) | 2014-10-07 | 2017-08-01 | 免疫医疗公司 | 抗体‑药物缀合物的新辅助剂用途 |
CN113045650A (zh) | 2014-12-19 | 2021-06-29 | 中外制药株式会社 | 抗-c5抗体及使用方法 |
CN107428823B (zh) | 2015-01-22 | 2021-10-26 | 中外制药株式会社 | 两种以上抗-c5抗体的组合与使用方法 |
JP6746845B2 (ja) | 2015-04-22 | 2020-08-26 | イミューノメディクス、インコーポレイテッドImmunomedics, Inc. | 循環trop−2陽性癌細胞の単離、検出、診断及び/または特徴付け |
CN107735104B (zh) | 2015-06-25 | 2022-05-03 | 免疫医疗公司 | 组合抗hla-dr抗体或抗trop-2抗体与微管抑制剂、parp抑制剂、布鲁顿激酶抑制剂或磷酸肌醇3-激酶抑制剂使癌症治疗结果显著改善 |
CA3001128A1 (en) | 2015-10-07 | 2017-04-13 | Apellis Pharmaceuticals, Inc. | Use of long-acting compstatin analog for treating a complement-mediated eye disorder |
TW201718014A (zh) | 2015-10-12 | 2017-06-01 | 諾華公司 | C5抑制劑於移植相關微血管病之用途 |
JP2018534930A (ja) | 2015-10-30 | 2018-11-29 | ジェネンテック, インコーポレイテッド | 抗d因子抗体及びコンジュゲート |
EP3368090A1 (en) | 2015-10-30 | 2018-09-05 | H. Hoffnabb-La Roche Ag | Anti-factor d antibody variant conjugates and uses thereof |
JP7102353B2 (ja) | 2016-06-14 | 2022-07-19 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 抗c5抗体及びそれらの使用 |
CA3026050A1 (en) | 2016-08-05 | 2018-02-08 | Chugai Seiyaku Kabushiki Kaisha | Composition for prophylaxis or treatment of il-8 related diseases |
TWI828672B (zh) | 2017-01-31 | 2024-01-11 | 日商中外製藥股份有限公司 | 用於治療或預防c5相關疾病的醫藥組合物以及治療或預防c5相關疾病的方法 |
KR20190139931A (ko) | 2017-04-07 | 2019-12-18 | 아펠리스 파마슈티컬스 인코포레이티드 | 투여 요법 및 관련 조성물 및 방법 |
MA51147A (fr) | 2017-12-13 | 2021-03-24 | Regeneron Pharma | Associations d'anticorps anti-c5 et utilisations associées |
WO2020027279A1 (en) | 2018-08-01 | 2020-02-06 | Chugai Seiyaku Kabushiki Kaisha | A pharmaceutical composition for use in the treatment or prevention of a c5-related disease and a method for treating or preventing a c5-related disease |
US20220275070A1 (en) | 2019-07-31 | 2022-09-01 | Hoffmann-La Roche Inc. | Dosage and administration regimen for the treatment or prevention of c5-related diseases by the use of the anti-c5 antibody crovalimab |
WO2021019033A1 (en) | 2019-07-31 | 2021-02-04 | F. Hoffmann-La Roche Ag | Dosage and administration regimen for the treatment or prevention of c5-related diseases by the use of the anti-c5 antibody crovalimab |
WO2021067526A1 (en) | 2019-10-02 | 2021-04-08 | Alexion Pharmaceuticals, Inc. | Complement inhibitors for treating drug-induced complement-mediated response |
CN111171149B (zh) * | 2020-02-23 | 2021-09-07 | 北京康普美特创新医药科技有限责任公司 | 一种抗补体c5分子的人源化单链抗体及其应用 |
WO2021231720A1 (en) | 2020-05-15 | 2021-11-18 | Alexion Pharmaceuticals, Inc. | Method of using extracellular vesicles to detect complement activation, and uses thereof to assess and/or monitor treatment of a complement-mediated disease |
CN114149501B (zh) * | 2020-12-11 | 2023-05-26 | 天士力生物医药股份有限公司 | 抗c5抗体及其应用 |
EP4342497A1 (en) | 2021-05-10 | 2024-03-27 | Kawasaki Institute of Industrial Promotion | Antibody having reduced binding affinity for antigen |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
JPS5896026A (ja) | 1981-10-30 | 1983-06-07 | Nippon Chemiphar Co Ltd | 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤 |
US4609546A (en) | 1982-06-24 | 1986-09-02 | Japan Chemical Research Co., Ltd. | Long-acting composition |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4766106A (en) | 1985-06-26 | 1988-08-23 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
US5506247A (en) | 1988-04-15 | 1996-04-09 | T Cell Sciences, Inc. | Compounds that inhibit complement and/or suppress immune activity |
US6395888B1 (en) * | 1996-02-01 | 2002-05-28 | Gilead Sciences, Inc. | High affinity nucleic acid ligands of complement system proteins |
US5679546A (en) | 1993-09-24 | 1997-10-21 | Cytomed, Inc. | Chimeric proteins which block complement activation |
WO1995025540A1 (en) * | 1994-03-23 | 1995-09-28 | Alexion Pharmaceuticals, Inc. | Method for reducing immune and hemostatic dysfunctions during extracorporeal circulation |
US6074642A (en) * | 1994-05-02 | 2000-06-13 | Alexion Pharmaceuticals, Inc. | Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis |
US5679345A (en) | 1994-06-02 | 1997-10-21 | The Johns Hopkins University | Method for preventing complement-dependent rejection of organ or tissue transplants |
US5546808A (en) | 1994-09-06 | 1996-08-20 | Harris Instrument Corporation | Apparatus and method for binocular measurement system |
US5463564A (en) | 1994-09-16 | 1995-10-31 | 3-Dimensional Pharmaceuticals, Inc. | System and method of automatically generating chemical compounds with desired properties |
CA2248772C (en) | 1996-03-13 | 2007-06-12 | John D. Lambris | Novel peptides which inhibit complement activation |
US5977076A (en) | 1997-04-14 | 1999-11-02 | Anderson; Byron E. | Method and material for inhibiting complement |
JP2002512624A (ja) | 1997-05-21 | 2002-04-23 | バイオベーション リミテッド | 非免疫原性タンパク質の製造方法 |
AU756490B2 (en) | 1997-08-26 | 2003-01-16 | Abgenix, Inc. | A process for inhibiting complement activation via the alternative pathway |
-
2001
- 2001-10-04 PT PT01977478T patent/PT1325033E/pt unknown
- 2001-10-04 WO PCT/US2001/031103 patent/WO2002030985A2/en active Application Filing
- 2001-10-04 ES ES09167955.5T patent/ES2483991T3/es not_active Expired - Lifetime
- 2001-10-04 CA CA2424379A patent/CA2424379C/en not_active Expired - Lifetime
- 2001-10-04 US US09/682,672 patent/US6534058B2/en not_active Expired - Lifetime
- 2001-10-04 ES ES01977478T patent/ES2333775T3/es not_active Expired - Lifetime
- 2001-10-04 EP EP10179315A patent/EP2281840A3/en not_active Withdrawn
- 2001-10-04 EP EP09167955.5A patent/EP2113516B1/en not_active Expired - Lifetime
- 2001-10-04 EP EP15154800.5A patent/EP2896631A1/en not_active Withdrawn
- 2001-10-04 EP EP01977478A patent/EP1325033B1/en not_active Expired - Lifetime
- 2001-10-04 AU AU2001296594A patent/AU2001296594A1/en not_active Abandoned
- 2001-10-04 EP EP16152143.0A patent/EP3031827A1/en not_active Withdrawn
- 2001-10-04 AT AT01977478T patent/ATE449791T1/de active
- 2001-10-04 DE DE60140618T patent/DE60140618D1/de not_active Expired - Lifetime
- 2001-10-04 DK DK01977478.5T patent/DK1325033T3/da active
-
2010
- 2010-03-10 HK HK10102519.6A patent/HK1134508A1/xx not_active IP Right Cessation
-
2015
- 2015-12-02 HK HK15111863.4A patent/HK1211043A1/xx unknown
-
2016
- 2016-12-07 HK HK16113934A patent/HK1225741A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
EP2113516B1 (en) | 2014-05-21 |
EP2281840A2 (en) | 2011-02-09 |
ATE449791T1 (de) | 2009-12-15 |
PT1325033E (pt) | 2010-04-15 |
AU2001296594A1 (en) | 2002-04-22 |
EP2113516A1 (en) | 2009-11-04 |
EP1325033A2 (en) | 2003-07-09 |
HK1211043A1 (en) | 2016-05-13 |
WO2002030985A3 (en) | 2002-12-05 |
ES2483991T3 (es) | 2014-08-08 |
HK1134508A1 (en) | 2010-04-30 |
US6534058B2 (en) | 2003-03-18 |
EP2281840A3 (en) | 2012-05-23 |
EP3031827A1 (en) | 2016-06-15 |
US20020041875A1 (en) | 2002-04-11 |
CA2424379C (en) | 2013-10-01 |
EP2896631A1 (en) | 2015-07-22 |
HK1225741A1 (zh) | 2017-09-15 |
DE60140618D1 (de) | 2010-01-07 |
EP1325033B1 (en) | 2009-11-25 |
WO2002030985A2 (en) | 2002-04-18 |
ES2333775T3 (es) | 2010-03-01 |
CA2424379A1 (en) | 2002-04-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK1325033T3 (da) | Inhibering af komplement C5 aktivering til behandlingen og forebyggelsen af forsinket xenograf- eller akut vaskulær afstødning | |
NO2006008I1 (no) | Natalizumab, anti alfa-4 integrin humanized monoclonal antibody | |
DK1054693T3 (da) | Inhibitorer af komplementaktivering | |
DK1265929T3 (da) | Anti-C2/C2a-inhibitorer til komplement aktivering | |
KR960704576A (ko) | CD40에 대한 항체(Antibodies to CD40) | |
WO2007062245A3 (en) | Human monoclonal antibody human cd134 (ox40) and methods of making and using same | |
WO1998057994A3 (en) | Opsonic and protective monoclonal and chimeric antibodies specific for lipoteichoic acid of gram positive bacteria | |
NZ611387A (en) | Selected antibodies binding to anionic phospholipids and aminophospholipids and their use in treatment | |
ATE421976T1 (de) | Fab fragmentbibliotheken und verfahren für deren verwendung | |
ATE509955T1 (de) | Humanisierte kollagen-antikörper und damit verbundene verfahren | |
ATE476989T1 (de) | Humanisierter monoklonaler antikörper gegen von- willebrand faktor | |
DE60334820D1 (de) | Verfahren zur kontrolle von krebs | |
WO2002074251A3 (en) | Monoclonal antibody therapy for pancreas cancer | |
DE69922834D1 (de) | Humanisierter antikörper spezifisch für das oberflächenantigen pre-s1 von hbv und dessen präparation | |
ATE370163T1 (de) | Antikörper zur isolierung und/oder identifizierung mesenchymaler stammzellen und verfahren zur isolierung und/oder identifizierung mesenchymaler stammzellen | |
DK1222929T3 (da) | Fremgangsmåde og farmaceutisk sammensætning til forebyggelse og/eller behandling af systematisk betændelsesreaktionssyndrom | |
DK1334983T3 (da) | Inhiberende monoklonalt antistof med proeasen, som aktiverer blodkoaguleringsfaktor VII | |
IL139571A0 (en) | A humanized antibody that binds to verotoxin, methods for the production thereof and pharmaceutical compositions containing the same | |
HUP0003029A2 (hu) | Ankrod specifikus monoklonális antitestek, antitestfragmentumok, keverékeik és alkalmazásuk |